HCT With PTCy in Higher-risk MDS
- Conditions
- Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 113
- Registration Number
- NCT06098313
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT06068868
- Locations
- 🇺🇸
University of Maryland, Baltimore /ID# 253726, Baltimore, Maryland, United States
🇦🇺Monash Health - Monash Medical Centre /ID# 253841, Clayton, Victoria, Australia
🇺🇸City of Hope /ID# 253727, Duarte, California, United States
A Study to Asses Effectiveness and Treatment Management of Oral Venetoclax Tablets + Subcutaneously Injected Azacitidine in Adult Participants Ineligible for Intensive Chemotherapy With de Novo Acute Myeloid Leukemia (AML) in Italy
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06058741
- Locations
- 🇮🇹
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 259535, Bologna, Italy
🇮🇹Azienda Ospedaliera Universitaria Integrata di Verona /ID# 260809, Verona, Italy
🇮🇹Azienda Ospedaliero Universitaria Careggi /ID# 259766, Florence, Firenze, Italy
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Interventions
- Drug: NTQ2494 tablet
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
- Target Recruit Count
- 72
- Registration Number
- NCT06049667
- Locations
- 🇨🇳
Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05947344
- Locations
- 🇨🇳
the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT05924750
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
🇨🇳Institute of Hematology, the First Hospital of Harbin, Haerbin, Heilongjiang, China
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Servier Affaires Médicales
- Target Recruit Count
- 245
- Registration Number
- NCT05907057
- Locations
- 🇦🇹
AKH - Medizinische Universität Wien, Vienna, Austria
🇦🇹Klinikum Wels-Grieskirchen GmbH, Wels, Austria
🇫🇷Institut Paoli Calmettes, Marseille, Bouches-du-Rhône, France
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia RefractoryGranulocytic Sarcoma
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 17
- Registration Number
- NCT05854966
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT05834244
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: VEN+AZA-5
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Leipzig
- Target Recruit Count
- 45
- Registration Number
- NCT05833438
- Locations
- 🇩🇪
Helios Klinikum Berlin-Buch Klinik für Hämatologie und Stammzelltransplantation, Berlin, Germany
🇩🇪Klinikum Chemnitz gGmbH Klinik für lnnere Medizin Ill, Chemnitz, Germany
🇩🇪Carl-Thiem-Klinikum Cottbus gGmbH, Cottbus, Germany